David Chang, M.D., Ph.D., is a distinguished leader in the field of biotechnology, currently serving as the President and Chief Executive Officer at Allogene Therapeutics Inc. Dr. Chang's academic journey is marked by rigorous training and a deep commitment to advancing medical science. He earned his M.D. from the University of California, Los Angeles (UCLA), and his Ph.D. in Immunology from the University of Southern California. His early career included significant roles in clinical development and research at major pharmaceutical companies, where he honed his expertise in oncology and immunology. Prior to joining Allogene Therapeutics, Dr. Chang held key leadership positions that have shaped his approach to driving innovation in the biotech industry. He served as the Global Head of Cancer Immunotherapy at Kite Pharma, where he was instrumental in the development and commercialization of groundbreaking CAR T-cell therapies. His tenure at Kite Pharma was marked by the successful launch of Yescarta®, the first CAR T-cell therapy approved by the FDA for the treatment of certain types of large B-cell lymphoma. Dr. Chang's strategic vision and scientific acumen have been pivotal in advancing the field of cancer immunotherapy. As President and CEO of Allogene Therapeutics, Dr. Chang is at the helm of a company dedicated to revolutionizing cancer treatment through the development of allogeneic CAR T-cell therapies. Under his leadership, Allogene has made significant strides in building a robust pipeline of next-generation therapies aimed at making cancer treatment more accessible and effective. Dr. Chang's role involves overseeing the company's strategic direction, fostering a culture of innovation, and ensuring that Allogene remains at the forefront of the rapidly evolving field of cell therapy. His commitment to translating scientific breakthroughs into tangible patient benefits continues to drive Allogene's mission to transform the landscape of cancer care.